The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

PAREXEL International

  • PRXL
  • NASDAQ
  • Consumer Products
  • Latest 53.75
  • Currency US$
  • Change -0.34
  • Percent Change -0.629 %
  • Volume 378,389
  • Fri Jul 11, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 54.00
  • Previous Close 54.09
  • High 54.16
  • Low 53.15
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High03/18 57.25
  • 52-week Low11/25 37.53
  • Beta 1.219
  • Market Cap 3,042.25M
  • EPS 2.06
  • P/E 26.092
  • Forward P/E 20.28
  • PEG 1.57
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $2,208,080,000
  • Earnings $119,060,000
  • Return on Equity 18.34%

Cash Flow

  • Cash Flow --
  • Cash $298,650,000
  • Current Ratio 1.52

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $1,873,280,000
  • Liabilities $1,202,520,000
  • Liabilities-to-Equity Ratio 1.79

Price Ratios

  • Price to Sales 1.38
  • Price to Book 4.54
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Apr 29 $0.53 Aug 6 $0.61
Surprises Apr 29 5.66% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Jul 13, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Parexel International Corporation is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales.

Related Securities
Symbol Type Latest % Chg

Officers

  • Josef H. von Rickenbach Chairman of the Board and Chie
  • James F. Winschel, Jr. Senior Vice President and Chie
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

195 WEST ST
WALTHAM, MA
02451

Phone: (781)-487-9900
Fax: (781)-4870525

jill.baker@parexel.com
www.parexel.com

Ideas & Discussion

Live Discussion of PRXL on StockTwits